The concern about ACE/ARB and COVID-19: Time to hold your horses!
J Am Pharm Assoc (2003)
; 60(6): e88-e90, 2020.
Article
in English
| MEDLINE | ID: covidwho-703079
ABSTRACT
Concern about coronavirus 2019 (COVID-19) morbidity and mortality has drawn attention to the potential role of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) because the SARS-CoV-2 uses the ACE2 receptor as its point of entry into the body. It is not clear if and to what degree the SARS-CoV-2 virus affects the renin-angoiotensin system. Early studies from China which speculated on the role of ACE inhibition and ARBs did not evaluate the drug regimens. A vast body of evidence supports the use of ACE inhibitors and ARBs in hypertensive patients and patients with heart failure, and very little evidence has been acquired about their role in COVID-19. There is good evidence in support of the use of ACE inhibitors and ARBs in indicated patients with hypertension and heart failure, and clinicians should be reticent about abruptly withdrawing these drugs based on a paucity of evidence.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Angiotensin-Converting Enzyme Inhibitors
/
Angiotensin Receptor Antagonists
/
Angiotensin-Converting Enzyme 2
/
COVID-19 Drug Treatment
/
Heart Failure
/
Hypertension
Type of study:
Experimental Studies
Limits:
Animals
/
Humans
Language:
English
Journal:
J Am Pharm Assoc (2003)
Journal subject:
Pharmacy
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS